Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples - PubMed (original) (raw)
Clinical Trial
. 2006 Feb 13;40(2):389-96.
doi: 10.1016/j.jpba.2005.07.033. Epub 2005 Oct 21.
Affiliations
- PMID: 16243469
- DOI: 10.1016/j.jpba.2005.07.033
Clinical Trial
Quantitative assay of lorazepam and its metabolite glucuronide by reverse-phase liquid chromatography-tandem mass spectrometry in human plasma and urine samples
Olga Papini et al. J Pharm Biomed Anal. 2006.
Abstract
A LC/MS/MS method for the quantitative determination of lorazepam in human plasma and urine samples was developed and validated. The enantioselective assay allowed to separate the enantiomers and to verify the stereochemical instability of lorazepam. The linearity assessed for lorazepam unchanged was 0.2-20 ng of each enantiomer/ml plasma and 0.2-15 ng of each enantiomer/ml urine. The linearity assessed for total lorazepam (after enzymatic hydrolysis) was 1-30 ng of each enantiomer/ml plasma and 10-150 ng of each enantiomer/ml urine. The coefficients of variation obtained for the intra- and interassay precision were less than 15%. The method was applied to the investigation of the kinetic disposition and metabolism of racemic lorazepam administered as a single oral dose of 2 mg to a parturient. The occurrence of racemization required the calculation of the pharmacokinetic parameters as enantiomeric mixtures of lorazepam (t(1/2a) 3.5h; K(a) 0.198 ngh(-1); t(1/2) 11.5h; beta 0.060 h(-1); AUC(0-infinity) 192.1ngh/ml; CLt/f 2.41ml/minkg; Vd/f 173.5l; Fel 0.41%, and Cl(R) 0.0099 ml/minkg) and its metabolite lorazepam-glucuronide (t(1/2f) 1.2h; K(f) 0.578 h(-1); t(1/2) 16.6h; beta 0.042 h(-1); AUC(0-infinity) 207.6 ngh/ml; Fel 51.80%, and Cl(R) 98.32 ml/minkg). However, the determined confidence limits make the method suitable for application to clinical pharmacokinetic studies, even if the quantification of both the enantiomers is required.
Similar articles
- Kinetic disposition of lorazepam with focus on the glucuronidation capacity, transplacental transfer in parturients and racemization in biological samples.
Papini O, da Cunha SP, da Silva Mathes Ado C, Bertucci C, Moisés EC, de Barros Duarte L, de Carvalho Cavalli R, Lanchote VL. Papini O, et al. J Pharm Biomed Anal. 2006 Feb 13;40(2):397-403. doi: 10.1016/j.jpba.2005.07.021. Epub 2005 Sep 6. J Pharm Biomed Anal. 2006. PMID: 16143486 Clinical Trial. - A fast and sensitive liquid chromatographic-tandem mass spectrometric method for assay of lorazepam and application to pharmacokinetic analysis.
Zhu H, Luo J. Zhu H, et al. J Pharm Biomed Anal. 2005 Sep 1;39(1-2):268-74. doi: 10.1016/j.jpba.2005.02.024. Epub 2005 Apr 7. J Pharm Biomed Anal. 2005. PMID: 16085142 - Determination of bromazepam in human plasma by high-performance liquid chromatography with electrospray ionization tandem mass spectrometric detection: application to a bioequivalence study.
Andraus MH, Wong A, Silva OA, Wada CY, Toffleto O, Azevedo CP, Salvadori MC. Andraus MH, et al. J Mass Spectrom. 2004 Nov;39(11):1348-55. doi: 10.1002/jms.667. J Mass Spectrom. 2004. PMID: 15532067 - Metabolites of lorazepam: Relevance of past findings to present day use of LC-MS/MS in analytical toxicology.
Turfus SC, Braithwaite RA, Cowan DA, Parkin MC, Smith NW, Kicman AT. Turfus SC, et al. Drug Test Anal. 2011 Oct;3(10):695-704. doi: 10.1002/dta.305. Epub 2011 Aug 12. Drug Test Anal. 2011. PMID: 21837620 - Enantioselective determination of ornidazole in human plasma by liquid chromatography-tandem mass spectrometry on a Chiral-AGP column.
Du J, Ma Z, Zhang Y, Wang T, Chen X, Zhong D. Du J, et al. J Pharm Biomed Anal. 2013 Dec;86:182-8. doi: 10.1016/j.jpba.2013.07.048. Epub 2013 Aug 12. J Pharm Biomed Anal. 2013. PMID: 24004635
Cited by
- Toxicokinetics of Bisphenol A - Scientific Opinion of the Panel on Food additives, Flavourings, Processing aids and Materials in Contact with Food (AFC).
European Food Safety Authority (EFSA). European Food Safety Authority (EFSA). EFSA J. 2008 Jul 23;6(7):759. doi: 10.2903/j.efsa.2008.759. eCollection 2008 Jul. EFSA J. 2008. PMID: 37213849 Free PMC article. No abstract available. - Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients.
Carvalho TM, Cavalli Rde C, Cunha SP, de Baraldi CO, Marques MP, Antunes NJ, Godoy AL, Lanchote VL. Carvalho TM, et al. Eur J Clin Pharmacol. 2011 Jan;67(1):55-61. doi: 10.1007/s00228-010-0896-0. Epub 2010 Sep 17. Eur J Clin Pharmacol. 2011. PMID: 20848091 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources